Biotage AB
STO:BIOT

Watchlist Manager
Biotage AB Logo
Biotage AB
STO:BIOT
Watchlist
Price: 143.2 SEK 0.14% Market Closed
Market Cap: kr11.5B

Gross Margin

62.6%
Current
Improving
by 0.7%
vs 3-y average of 61.9%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
62.6%
=
Gross Profit
kr1.2B
/
Revenue
kr2B

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
62.6%
=
Gross Profit
kr1.2B
/
Revenue
kr2B

Peer Comparison

Country Company Market Cap Gross
Margin
SE
Biotage AB
STO:BIOT
11.5B SEK
Loading...
US
PerkinElmer Inc
LSE:0KHE
948.1B USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
177.8B USD
Loading...
US
Danaher Corp
NYSE:DHR
138B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
82.3T KRW
Loading...
CH
Lonza Group AG
SIX:LONN
33.5B CHF
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
265.3B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
31.9B USD
Loading...
US
Waters Corp
NYSE:WAT
29.1B USD
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
28.6B USD
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
24.6B USD
Loading...

Market Distribution

In line with most companies in Sweden
Percentile
67th
Based on 1 864 companies
67th percentile
62.6%
Low
-855 316.7% — 30.8%
Typical Range
30.8% — 66%
High
66% — 113 764.6%
Distribution Statistics
Sweden
Min -855 316.7%
30th Percentile 30.8%
Median 44.8%
70th Percentile 66%
Max 113 764.6%

Biotage AB
Glance View

Biotage AB, a Swedish life sciences company, has carved a significant niche within the analytical and organic chemistry sectors since its inception. The company's core operations revolve around the development of innovative solutions designed to facilitate drug discovery, genetic research, and infection diagnostics. By offering products that simplify and accelerate chemical synthesis, Biotage has become essential to the pharmaceutical and biotechnology industries. The company's product lineup includes automated sample preparation systems, flash chromatography instruments, and peptide synthesis solutions. These tools are indispensable for researchers and lab technicians, making complex laboratory processes more efficient and less time-consuming. Financially, Biotage generates revenue through the sale and distribution of its cutting-edge laboratory instruments and their accompanying consumables. In addition to equipment sales, the company also engages in service contracts and after-sales support, which provides a steady stream of recurring income. This dual model of one-time equipment purchases combined with ongoing service and supply needs ensures a stable revenue base. Biotage stays competitive by continually innovating and refining its technology, ensuring its solutions remain indispensable to scientists addressing critical challenges in medicine, environmental testing, and other fields that demand highly precise chemical processes.

BIOT Intrinsic Value
115.48 SEK
Overvaluation 19%
Intrinsic Value
Price
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
62.6%
=
Gross Profit
kr1.2B
/
Revenue
kr2B
What is Biotage AB's current Gross Margin?

The current Gross Margin for Biotage AB is 62.6%, which is above its 3-year median of 61.9%.

How has Gross Margin changed over time?

Over the last 3 years, Biotage AB’s Gross Margin has increased from 61.2% to 62.6%. During this period, it reached a low of 60.2% on Mar 31, 2023 and a high of 62.9% on Jun 30, 2024.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett